南模生物联合举办第二届中美冠科国际生物医药研讨会圆满成功
2019年6月19日，南模生物同中美冠科在上海联合举办了第二届中美冠科国际生物医药研讨会——癌症治疗前瞻，聚焦行业最前沿肿瘤药物发现。此次专题论坛汇集了顶尖生物技术、制药企业的R&D和临床前团队，对现行技术以及如何推进未来发展方向进行了深入探讨。
议题包括：
•像类器官（Organoids）这样的新型平台是如何加强肿瘤药物研发计划
•最新前沿in vivo 癌症建模和肿瘤/免疫肿瘤模型
•如何克服将中国科技引入全球市场的挑战
会上，南模生物副总经理孙瑞林博士就“人源化小鼠模型在肿瘤抗体免疫中的应用”这一主题进行了报告，为大家呈现了公司最新的人源化小鼠模型进展及未来在生物医药领域的规划与布局。报告内容极大地吸引了参会嘉宾，现场气氛活跃。
图1 孙瑞博士在会议现场进行报告
你也可能感兴趣
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
